Difference between revisions of "SPECT Biomarker Ctte"
Jump to navigation
Jump to search
m |
|||
(55 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
+ | {{TOCright}} | ||
+ | :Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD | ||
+ | |||
+ | * [http://tinyurl.com/QIBA-SPECT-Roster Roster] | ||
+ | |||
==Project Snapshot== | ==Project Snapshot== | ||
The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging. | The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging. | ||
− | |||
'''Under consideration:''' | '''Under consideration:''' | ||
Line 7: | Line 11: | ||
*quantifying organs, like the liver, for dosimetry as potential use cases | *quantifying organs, like the liver, for dosimetry as potential use cases | ||
− | + | '''Established Task Forces''' currently working toward a first Profile titled: <font color=blue>''Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease''</font> | |
− | '''Established Task Forces | ||
− | |||
− | <font color=blue>''Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease''</font> | ||
* Image Acquisition and Image Processing for DaTscan – ''Dr. Dewaraja'' | * Image Acquisition and Image Processing for DaTscan – ''Dr. Dewaraja'' | ||
Line 17: | Line 18: | ||
* Clinical / Literature Review – ''Dr. Seibyl'' | * Clinical / Literature Review – ''Dr. Seibyl'' | ||
− | ==Meetings/Call Summaries== | + | ==Recent Meetings/Call Summaries== |
− | |||
− | + | *[[Media:02 16 2018 QIBA SPECT Call Summary-FINAL.pdf|February 16, 2018]] | |
− | == | + | *[[Media:01 19 2018 QIBA SPECT Call Summary-FINAL.pdf|January 19, 2018]] |
+ | *[[Media:10 20 2017 QIBA SPECT Call Summary-FINAL.pdf|October 20, 2017]] | ||
+ | |||
+ | '''''[[SPECT BC Call Summaries Archive]]''''' | ||
+ | |||
+ | ==Literature Review (Profile 1.0)== | ||
+ | *[[Media:QIBA SPECT Literature Review-22 March 2016.pdf | QIBA Literature Review Slides for Profile 1.0 - Dr. Seibyl]] ''March 22, 2016'' | ||
+ | |||
+ | *[[Media:QIBA SPECT Literature Review-22 March 2016.docx | QIBA Literature Review for Profile 1.0 (Word document) - Dr. Seibyl]] ''March 22, 2016'' | ||
==Profile Development== | ==Profile Development== | ||
− | *[[Media:001. | + | *[[Media:001.QIBA SPECT Ioflupane Profile.v1.0 post-public comments.2017 08 29.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.1), August 28, 2017]] |
+ | |||
+ | *[[Media:001.QIBA SPECT Ioflupane Profile.v1.0 post-public comments.clean copy.2017 06 26.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.1), June 26, 2017]] | ||
+ | |||
+ | *[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016]] | ||
+ | |||
+ | *[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|QIBA Profile Checklist: SPECT Profile Conformance]] | ||
− | *[[Media:001 QIBA_SPECT_Profile v0 | + | *[[Media:001.QIBA_SPECT_Profile.v0.1_2016.05.10.docx | QIBA DRAFT Profile with tracked changes - {Dr. Miyaoka}]] ''May 10, 2016'' |
− | + | *[[Media:001.QIBA_SPECT_Profile.v0.1_2016.05.1.docx | QIBA DRAFT Profile with tracked changes - {Dr. Dewaraja}]] ''May 1, 2016'' | |
− | |||
− | + | *[[Media:001.QIBA_SPECT_Profile.v0.1_2016.04.15b.docx | QIBA DRAFT Profile with tracked changes - {Dr. Mozley}]] ''April 15, 2016'' | |
+ | *[[Media:001.QIBA_SPECT_Profile.v0.1_2016.04.05.docx | QIBA DRAFT Profile with tracked changes for recent additions and homework - {Dr. E. Frey}]] ''April 5, 2016'' | ||
+ | |||
+ | *[[Profile drafts|Archived past versions of the Profile]] | ||
− | |||
==Reference Materials== | ==Reference Materials== | ||
+ | |||
+ | *[[Media:Literature Review 23Aug2016.pdf | QIBA SPECT TF presentation slides - Dr. Seibyl]] ''August 23, 2016'' | ||
+ | |||
+ | *[[Media:QIBA big BC agenda.2016 07 15-yuniupdated2.pdf | QIBA SPECT BC presentation slides - Dr. Mozley]] ''July 15, 2016'' | ||
+ | |||
+ | *[[Media:qiba agenda 12 july_rsm.pdf | QIBA SPECT BC presentation slides - Dr. Miyaoka]] ''July 12, 2016'' | ||
+ | |||
+ | *[[Media:qiba agenda 10 may_rsm_v2.pdf | QIBA SPECT BC presentation slides - Dr. Miyaoka]] ''May l0, 2016'' | ||
+ | |||
+ | *[[Media:Image Acquisition and Reconstruction.pdf | QIBA SPECT BC presentation slides - Dr. Dewaraja]] ''May 5, 2016'' | ||
+ | |||
+ | *[[Media:DATscan_DRO.pdf | QIBA SPECT BC presentation slides - Dr. Miyaoka]] ''April 22, 2016'' | ||
+ | |||
+ | *[[Media:QIBA SPECT Quantitative and Image Analysis-8 March 2016.pdf | QIBA SPECT BC presentation slides - Dr. Seibyl]] ''March 8, 2016'' | ||
*[[Media:QIBA SPECT DAcq and Proc-Feb 2016.pdf | QIBA SPECT BC presentation slides - Dr. Frey]] ''February 2, 2016'' | *[[Media:QIBA SPECT DAcq and Proc-Feb 2016.pdf | QIBA SPECT BC presentation slides - Dr. Frey]] ''February 2, 2016'' |
Latest revision as of 18:46, 21 December 2023
- Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD
Project Snapshot
The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.
Under consideration:
- quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
- quantifying organs, like the liver, for dosimetry as potential use cases
Established Task Forces currently working toward a first Profile titled: Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease
- Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
- Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
- Phantoms / DRO Group – Drs. Dickson and Zimmerman
- Clinical / Literature Review – Dr. Seibyl
Recent Meetings/Call Summaries
SPECT BC Call Summaries Archive
Literature Review (Profile 1.0)
- QIBA Literature Review Slides for Profile 1.0 - Dr. Seibyl March 22, 2016
Profile Development
- QIBA DRAFT Profile with tracked changes - {Dr. Mozley} April 15, 2016
- QIBA DRAFT Profile with tracked changes for recent additions and homework - {Dr. E. Frey} April 5, 2016
Reference Materials
- QIBA SPECT TF presentation slides - Dr. Seibyl August 23, 2016
- QIBA SPECT BC presentation slides - Dr. Mozley July 15, 2016
- QIBA SPECT BC presentation slides - Dr. Miyaoka July 12, 2016
- QIBA SPECT BC presentation slides - Dr. Miyaoka May l0, 2016
- QIBA SPECT BC presentation slides - Dr. Dewaraja May 5, 2016
- QIBA SPECT BC presentation slides - Dr. Miyaoka April 22, 2016
- QIBA SPECT BC presentation slides - Dr. Seibyl March 8, 2016
- QIBA SPECT BC presentation slides - Dr. Frey February 2, 2016
- QIBA SPECT BC presentation slides - Dr. Buchert February 2, 2016
- QIBA SPECT BC presentation slides - Dr. Seibyl January 22, 2016
- I-123 DAT SCAN - Acquisition and Reconstruction Task Force presentation slides - Dr. Dewaraja January 5, 2016
- QIBA Claim Statement Types - Dr. Obuchowski November 20, 2015
- 03.20.2015 Link to papers of the group in Umeå that are collaborating with Dr. Ljungberg:
- The PI for this is Anne Larsson, PhD: http://www.ncbi.nlm.nih.gov/pubmed/?term=dat+scan+Larsson+A